The case for Biohaven (NYSE: BHVN) and SK Biopharmaceuticals' global licensing deal is that it delivers $400 million in near-term, non-dilutive cash to New Haven-based Biohaven while handing opakalim to a commercial infrastructure Biohaven did not have to build. The risk is that the deal's most valuable layer, tiered U.S. royalties in the mid-teens to low twenties on net sales of opakalim, sits entirely behind a binary clinical event. Topline data from the RISE3 Phase 2/3 trial are not expected until the second half of 2026.
Under the terms announced August 26, SK Biopharmaceuticals receives an exclusive worldwide license to Biohaven's Kv7 ion channel platform and its lead candidate, opakalim (BHV-7000), a selective Kv7.2/7.3 potassium channel activator in Phase 2/3 development for focal epilepsy. Biohaven collects $350 million at closing and $50 million in 2027. It is also eligible for an additional $150 million in development and regulatory milestones, with total upfront and milestone consideration up to $795 million per the filing. SK Biopharmaceuticals further assumes Knopp Biosciences and future Kv7 milestone obligations totaling $245 million and a mid-single digit royalty to Knopp, transferring a meaningful share of Biohaven's go-forward cash obligations to the partner.
The commercial read-through leans on what SK Biopharmaceuticals has already built. Through its U.S. subsidiary SK Life Science, the Seoul-based company markets XCOPRI (cenobamate) for partial-onset seizures in adults, running a neurology field force of more than 150 professionals and reporting steady double-digit XCOPRI growth, per the company. Biohaven Chairman and CEO Vlad Coric said SK Biopharmaceuticals is the only company to have launched a new antiseizure medicine for focal seizures in the U.S. since 2016. SK Bio's President and CEO Donghoon Lee described opakalim as a complementary addition to an existing epilepsy portfolio, pointing to a mechanism and tolerability profile that could extend the company's reach to patients who need additional treatment options.
The counterargument is blunt. The $400 million in near-term cash arrives regardless of what RISE3 shows. The royalty tier does not. A failed or inconclusive Phase 2/3 readout strips the milestone and royalty stack from the story, leaving Biohaven with a stronger balance sheet but no commercial product. Opakalim is designed as a once-daily oral treatment without titration and with a tolerability profile intended to reduce sedation and dizziness associated with many existing antiseizure medicines. Whether that profile translates into Phase 2/3 data is a question only RISE3 can answer.
On balance, the structure is sensible for a company seeking runway without diluting shareholders. SK Biopharmaceuticals carries clinical and commercial execution risk from here. Biohaven retains a royalty position it could not have self-funded through launch. The line to watch is the RISE3 topline, expected in the second half of 2026.